Diagnostics (Feb 2022)

The Value of APTw CEST MRI in Routine Clinical Assessment of Human Brain Tumor Patients at 3T

  • Julia P. Lingl,
  • Arthur Wunderlich,
  • Steffen Goerke,
  • Daniel Paech,
  • Mark E. Ladd,
  • Patrick Liebig,
  • Andrej Pala,
  • Soung Yung Kim,
  • Michael Braun,
  • Bernd L. Schmitz,
  • Meinrad Beer,
  • Johannes Rosskopf

DOI
https://doi.org/10.3390/diagnostics12020490
Journal volume & issue
Vol. 12, no. 2
p. 490

Abstract

Read online

Background. With fast-growing evidence in literature for clinical applications of chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI), this prospective study aimed at applying amide proton transfer-weighted (APTw) CEST imaging in a clinical setting to assess its diagnostic potential in differentiation of intracranial tumors at 3 tesla (T). Methods. Using the asymmetry magnetization transfer ratio (MTRasym) analysis, CEST signals were quantitatively investigated in the tumor areas and in a similar sized region of the normal-appearing white matter (NAWM) on the contralateral hemisphere of 27 patients with intracranial tumors. Area under curve (AUC) analyses were used and results were compared to perfusion-weighted imaging (PWI). Results. Using APTw CEST, contrast-enhancing tumor areas showed significantly higher APTw CEST metrics than contralateral NAWM (AUC = 0.82; p p p p > 0.05). PWI showed results comparable to APTw CEST in glioblastoma (p < 0.01). Conclusions. This prospective study confirmed the high diagnostic potential of APTw CEST imaging in a routine clinical setting to differentiate brain tumors.

Keywords